478 related articles for article (PubMed ID: 30041236)
1. Effect of Apolipoprotein E ɛ4 Carrier Status on Cognitive Response to Acetylcholinesterase Inhibitors in Patients with Alzheimer's Disease: A Systematic Review and Meta-Analysis.
Cheng YC; Huang YC; Liu HC
Dement Geriatr Cogn Disord; 2018; 45(5-6):335-352. PubMed ID: 30041236
[TBL] [Abstract][Full Text] [Related]
2. APOE-ɛ4 Carrier Status and Donepezil Response in Patients with Alzheimer's Disease.
Waring JF; Tang Q; Robieson WZ; King DP; Das U; Dubow J; Dutta S; Marek GJ; Gault LM
J Alzheimers Dis; 2015; 47(1):137-48. PubMed ID: 26402762
[TBL] [Abstract][Full Text] [Related]
3. Butyrylcholinesterase K and Apolipoprotein E-ɛ4 Reduce the Age of Onset of Alzheimer's Disease, Accelerate Cognitive Decline, and Modulate Donepezil Response in Mild Cognitively Impaired Subjects.
De Beaumont L; Pelleieux S; Lamarre-Théroux L; Dea D; Poirier J;
J Alzheimers Dis; 2016 Oct; 54(3):913-922. PubMed ID: 27567841
[TBL] [Abstract][Full Text] [Related]
4. Influence of apolipoprotein E varepsilon4 on rates of cognitive and functional decline in mild cognitive impairment.
Whitehair DC; Sherzai A; Emond J; Raman R; Aisen PS; Petersen RC; Fleisher AS;
Alzheimers Dement; 2010 Sep; 6(5):412-9. PubMed ID: 20813342
[TBL] [Abstract][Full Text] [Related]
5. Effect of APOE genotype status on targeted clinical trials outcomes and efficiency in dementia and mild cognitive impairment resulting from Alzheimer's disease.
Kennedy RE; Cutter GR; Schneider LS
Alzheimers Dement; 2014 May; 10(3):349-59. PubMed ID: 23712001
[TBL] [Abstract][Full Text] [Related]
6. Apolipoprotein E epsilon4 allele differentiates the clinical response to donepezil in Alzheimer's disease.
Bizzarro A; Marra C; Acciarri A; Valenza A; Tiziano FD; Brahe C; Masullo C
Dement Geriatr Cogn Disord; 2005; 20(4):254-61. PubMed ID: 16103669
[TBL] [Abstract][Full Text] [Related]
7. Effect of apolipoprotein E and butyrylcholinesterase genotypes on cognitive response to cholinesterase inhibitor treatment at different stages of Alzheimer's disease.
Patterson CE; Todd SA; Passmore AP
Pharmacogenomics J; 2011 Dec; 11(6):444-50. PubMed ID: 20644562
[TBL] [Abstract][Full Text] [Related]
8. Apolipoprotein E genotype-specific short-term cognitive benefits of treatment with the antihypertensive nilvadipine in Alzheimer's patients--an open-label trial.
Kennelly S; Abdullah L; Kenny RA; Mathura V; Luis CA; Mouzon B; Crawford F; Mullan M; Lawlor B
Int J Geriatr Psychiatry; 2012 Apr; 27(4):415-22. PubMed ID: 21560164
[TBL] [Abstract][Full Text] [Related]
9. Apolipoprotein E ɛ4 (APOE ɛ4) Allele is Associated with Long Sleep Duration Among Elderly with Cognitive Impairment.
Basta M; Zaganas I; Simos P; Koutentaki E; Dimovasili C; Mathioudakis L; Bourbouli M; Panagiotakis S; Kapetanaki S; Vgontzas A
J Alzheimers Dis; 2021; 79(2):763-771. PubMed ID: 33361595
[TBL] [Abstract][Full Text] [Related]
10. Default Mode Network Connectivity Moderates the Relationship Between the APOE Genotype and Cognition and Individualizes Identification Across the Alzheimer's Disease Spectrum.
Zhu Y; Gong L; He C; Wang Q; Ren Q; Xie C;
J Alzheimers Dis; 2019; 70(3):843-860. PubMed ID: 31282419
[TBL] [Abstract][Full Text] [Related]
11. Total apolipoprotein E levels and specific isoform composition in cerebrospinal fluid and plasma from Alzheimer's disease patients and controls.
Martínez-Morillo E; Hansson O; Atagi Y; Bu G; Minthon L; Diamandis EP; Nielsen HM
Acta Neuropathol; 2014 May; 127(5):633-43. PubMed ID: 24633805
[TBL] [Abstract][Full Text] [Related]
12. Chain Mediation Analysis of the Effects of Nutrition and Cognition on the Association of Apolipoprotein E ɛ4 with Neuropsychiatric Symptoms in Alzheimer's Disease.
Jiang J; Hong Y; Li W; Wang A; Jiang S; Jiang T; Wang Y; Wang L; Yang S; Ren Q; Zou X; Xu J
J Alzheimers Dis; 2023; 96(2):669-681. PubMed ID: 37840496
[TBL] [Abstract][Full Text] [Related]
13. Most rapid cognitive decline in APOE epsilon4 negative Alzheimer's disease with early onset.
van der Vlies AE; Koedam EL; Pijnenburg YA; Twisk JW; Scheltens P; van der Flier WM
Psychol Med; 2009 Nov; 39(11):1907-11. PubMed ID: 19335933
[TBL] [Abstract][Full Text] [Related]
14. Cilostazol as an add-on therapy for patients with Alzheimer's disease in Taiwan: a case control study.
Tai SY; Chen CH; Chien CY; Yang YH
BMC Neurol; 2017 Feb; 17(1):40. PubMed ID: 28231822
[TBL] [Abstract][Full Text] [Related]
15. Association between white matter hyperintensity severity and cognitive impairment according to the presence of the apolipoprotein E (APOE) ε4 allele in the elderly: retrospective analysis of data from the CREDOS study.
Son SJ; Lee KS; Lee Y; Baek JH; Choi SH; Na DL; Seo SW; Oh BH; Hong CH
J Clin Psychiatry; 2012 Dec; 73(12):1555-62. PubMed ID: 23146133
[TBL] [Abstract][Full Text] [Related]
16. Memantine and Acetylcholinesterase Inhibitor Use in Alzheimer's Disease Clinical Trials: Potential for Confounding by Indication.
Huisa BN; Thomas RG; Jin S; Oltersdorf T; Taylor C; Feldman HH
J Alzheimers Dis; 2019; 67(2):707-713. PubMed ID: 30636733
[TBL] [Abstract][Full Text] [Related]
17. Effects of Apolipoprotein E ɛ4 and Risk Factors on Domains of Cognition in Mild Cognitive Impairment and Dementia.
Han SH; Noh DH; Jo EJ; Kam KY
J Alzheimers Dis; 2022; 87(3):1181-1188. PubMed ID: 35466935
[TBL] [Abstract][Full Text] [Related]
18. APOE ε4 moderates amyloid-related memory decline in preclinical Alzheimer's disease.
Lim YY; Villemagne VL; Pietrzak RH; Ames D; Ellis KA; Harrington K; Snyder PJ; Martins RN; Masters CL; Rowe CC; Maruff P;
Neurobiol Aging; 2015 Mar; 36(3):1239-44. PubMed ID: 25559335
[TBL] [Abstract][Full Text] [Related]
19. APOE genotype and neuroimaging markers of Alzheimer's disease: systematic review and meta-analysis.
Liu Y; Yu JT; Wang HF; Han PR; Tan CC; Wang C; Meng XF; Risacher SL; Saykin AJ; Tan L
J Neurol Neurosurg Psychiatry; 2015 Feb; 86(2):127-34. PubMed ID: 24838911
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
